Thrombotic microangiopathy after renal transplantation: Current insights in de novo and recurrent disease

Table 2 Risk of atypical hemolytic uremic syndrome recurrence according to the implicated genetic abnormality

Genemutation	Location	Functionalimpact	Mutation frequencyin aHUS (%)	Recurrence after transplantation (%)
CFH	Plasma	Loss	20-30	75-90
CFI	Plasma	Loss	2-12	45-80
CFB	Plasma	Gain	1-2	100
C3	Plasma	Gain	5-10	40-70
MCP	Membrane	Loss	10-15	15-20
THBD	Membrane	Loss	5	One case
HomozygousCFHR1 del (3%-8%)	Circulating	Undetermined	14-23 (> 90% with anti-CHF AB)	NA

Adapted from Salvadori et al[74]. NA: Not available; CFH: Complement factor H; CFI: Complement factor I; CFB: Complement factor B; C3: Complement component 3; MCP: Membrane cofactor protein; THBD: Thrombomodulin.